parental cells. Uptake of labeled EV and exosomal miRNA of BC cells in hTERT-FB could be confirmed. Co-cultivation of tumor-associated and normal EV and normal BF resulted in increased proliferation and migration rates in normal BF independently from the invasiveness of donor BC cells, but cell-type specific.
INTRODUCTION AND OBJECTIVES:
Urothelial bladder canrcinoma (UBC) is characterized by a large number of genetic alteration. Urinary DNA is promising resources for liquid biopsy in urological malignancies. In this study, we performed genomic profiling of UBC and matched urinary cell free DNA (cfDNA) and exosomal DNA (exoDNA).
METHODS: We included 9 patients who underwent surgery for UBC. Fresh frozen tumor sample and normal blood sample was used for genomic profiling of UBC. We also performed genomic profiling of matched urinary DNA to investigate whether genomic alteration in tumor samples are echoed in urinary DNA. Urinary exoDNA was extracted from urinary exosome which was isolated by ExoQuick and urinary cfDNA was extracted by commercial kit using magnetic bead. We performed 9 gene target sequencing for somatic mutation analysis and low depth whole genome sequencing (ldWGS) for copy number analysis.
RESULTS: We found 17 somatic mutations in 6 patients, and 17 included 6 nonsynonymous SNVs, 3 stopgain SNVs, 2 frameshift deletion and 6 synonymous SNVs. Of 17 somatic mutations, 12 were identified in cfDNA and exoDNA with the mean allele frequency of 54.5% and 65.6%, respectively. Mean depth of cfDNA and exoDNA was 1721X and 1627X, respectively ( Figure 1 ). In copy number analysis, mean 20.4% of whole genome region was covered by >1X. Copy number plots of cfDNA and exoDNA showed similar pattern with those of tumor samples. When we compare the log2 ratio of 100k bin size in whole genome regions, Pearson correlation coefficients of tumor vs cfDNA (0.481) and tumor vs exoDNA (0.455) were higher than that of tumor vs normal (0.086) (Figure 2) . CONCLUSIONS: Both urinary cfDNA and exoDNA were representative of the entire human genome and allowed genomic profiling of UBC. Specifically, copy number analysis using ldWGS has potential to be used as tools developing biomarker with low cost and whole genome coverage. 
MP54-17 GLUCOCORTICOID RECEPTOR AND FOXO1 EXPRESSION IN BLADDER CANCER AS AN INDEPENDENT PROGNOSTICATOR
Hiroki Ide*, Baltimore, MD; Satoshi Inoue, Taichi Mizushima, Rochester, NY; George Netto, Birmingham, AL; Hiroshi Miyamoto, Rochester, NY INTRODUCTION AND OBJECTIVES: Our preliminary studies suggest that FOXO1, a transcriptional factor known to induce apoptosis through the PI3K-Akt pathway, functions as a tumor suppressor in bladder cancer. Meanwhile, cross-talk between FOXO1 and glucocorticoid receptor (GR) signals has been demonstrated in non-urothelial cancer cells. The current study aims to determine the association between FOXO1 and GR expression in bladder cancer and its prognostic significance.
METHODS: We immunohistochemically stained for GR, FOXO1, and p-FOXO1 (a phosphorylated/inactive form), in bladder cancer tissue microarrays consisting of 51 low-grade non-muscleinvasive, 27 high-grade non-muscle-invasive, and 51 high-grade muscle-invasive tumors. We then assessed the relationship between their expression and clinicopathologic features of our patient cohort.
RESULTS: GR was positive in 109 [73.6%; 39 (26.3%) weak (1þ), 39 (26.3%) moderate (2þ), 31 (21.0%) strong (3þ)] tumors, while FOXO1 and p-FOXO1 were positive in 17 [13.2%; 16 (12.4%) 1þ, 1 (0.8%) 2þ] and 71 [55.1%; 57 (44.2%) 1þ, 14 (10.9%) 2þ] tumors, respectively. Eleven (21.6%) low-grade versus 4 (5.1%) high-grade tumors (P¼0.006) and 14 (17.9%) non-muscle-invasive versus 1 (2.0%) muscle-invasive tumors (P¼0.009) showed GR(2þ/3þ)/FOXO1(1þ/ 2þ). Similarly, 3 (5.9%) low-grade versus 31 (39.7%) high-grade tumors (P<0.001) and 12 (15.4%) non-muscle-invasive versus 22 (43.1%) muscle-invasive tumors (P<0.001) showed GR(0/1þ)/p-FOXO1(1þ/ 2þ). Of note, GR expression was positively and negatively associated with FOXO1 (P¼0.002) and p-FOXO1 (P¼0.009), respectively. KaplanMeier and log-rank tests revealed that patients with GR(2þ/3þ) and FOXO1(þ) non-muscle-invasive tumor (N¼14) had a significantly lower risk of tumor recurrence (P¼0.030) and that those with GR(0/1þ) and p-FOXO1(þ) muscle-invasive tumor (N¼22) had a significantly higher risk of disease progression (P¼0.012). Multivariate analysis further revealed combinations of GR and FOXO1 or p-FOXO1 as independent predictors of recurrence of non-muscle-invasive bladder cancer (HR¼0.144; 95%CI¼0.020-1.056; P¼0.057) or progression of muscleinvasive bladder cancer (HR¼2.520; 95%CI¼1.226-5.182; P¼0.012), respectively.
CONCLUSIONS: Activities of GR and FOXO1 appear to be significantly correlated in bladder cancer. Moreover, they precisely predict the prognosis of patients with either non-muscle-invasive or muscle-invasive bladder tumor.
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